Meeting
2017 ASCO Annual Meeting
Role of time to switch from ipilimumab to anti-PD1 in anti-PD1 efficacy within the French national cohort, MelBase.
Authors
Clara Allayous
Dermatology, Hôpital Saint-Louis, Paris, France
Clara Allayous , Stéphane Dalle , Marie Thérèse Leccia , Francois Aubin , Laurent Mortier , Marie- Beylot-Barry , Philippe Saiag , Sophie Dalac-Rat , Jean Philippe Lacour , Eve Maubec , Vincent Descamps , Bernard Guillot , Thierry Lesimple , Julie De Quatrebarbes , Jean-Philippe Arnault , Pierre-Emmanuel Stoebner , Raphael Porcher , Alice Ballon , Bastien Oriano , Celeste Lebbe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9551)
DOI
10.1200/JCO.2017.35.15_suppl.9551
Abstract #
9551
Poster Bd #
159
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets).
First Author: James J. Harding
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu
Poster
2018 ASCO Annual Meeting
Ipilimumab and radiation in patients with unresectable melanoma brain metastases: A multicenter, open label, phase-2, Spanish Melanoma Group (GEM) study (NCT-2013-001132-22).
First Author: Jose A. Lopez-Martin
Poster
2016 ASCO Annual Meeting
Immunotherapy-treated melanoma brain metastases within the French national cohort, MelBase.
First Author: Clara Allayous